Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025.

Type
Public
HQ
Gaithersburg, US
Founded
1998
Size (employees)
1,098 (est)-15%
Emergent Biosolutions was founded in 1998 and is headquartered in Gaithersburg, US

Emergent Biosolutions Office Locations

Emergent Biosolutions has offices in Gaithersburg, Washington, Lansing, Winnipeg and in 5 other locations
Gaithersburg, US (HQ)
400 400 Professional Dr
Baltimore, US
1111 S Paca St
Seattle, US
1050 2401 4th Ave
Richmond, GB
Kew Rd
Baltimore, US
5901 E Lombard St
Hattiesburg, US
46 Shelby Thames Dr
Show all (10)

Emergent Biosolutions Data and Metrics

Emergent Biosolutions Financial Metrics

Emergent Biosolutions's revenue was reported to be $488.8 m in FY, 2016 which is a 0% decrease from the previous period.
USD

Revenue (FY, 2016)

488.8 m

Revenue growth (FY, 2015 - FY, 2016), %

(0%)

Net income (FY, 2016)

51.8 m

EBIT (FY, 2016)

105.5 m

Market capitalization (21-Jul-2017)

1.8 b

Cash (31-Dec-2016)

271.5 m
Emergent Biosolutions's current market capitalization is $1.8 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

404.5 m489.3 m488.8 m

Revenue growth, %

21%(0%)

R&D expense

108.3 m

General and administrative expense

143.7 m

Operating expense total

252 m

EBIT

89.2 m141.5 m105.5 m

EBIT margin, %

22%29%22%

Interest expense

(8.2 m)(6.5 m)(7.6 m)

Interest income

1.1 m

Income tax expense

29.9 m44.3 m36.7 m

Net Income

36.7 m62.9 m51.8 m
USDFY, 2014FY, 2015FY, 2016

Cash

280.5 m312.8 m271.5 m

Accounts Receivable

58.8 m120.8 m138.5 m

Inventories

65.7 m76.9 m74 m

Current Assets

432.2 m538.6 m510.2 m

PP&E

314 m331.9 m376.4 m

Total Assets

938.7 m1 b970.1 m

Accounts Payable

40.9 m46 m34.6 m

Current Liabilities

92.9 m99.6 m105.9 m

Total Liabilities

373.9 m

Additional Paid-in Capital

274.2 m318 m352.4 m

Retained Earnings

288.3 m351.1 m254.5 m

Total Equity

553.2 m660 m596.2 m

Financial Leverage

1.7 x1.6 x1.6 x
USDFY, 2014FY, 2015FY, 2016

Net Income

36.7 m62.9 m51.8 m

Accounts Receivable

21.4 m(64 m)(22.4 m)

Inventories

4.2 m(11.3 m)(9 m)

Accounts Payable

(9.3 m)4.7 m(14.8 m)

Cash From Operating Activities

112.3 m44.5 m53.5 m

Purchases of PP&E

(30.7 m)(44.8 m)(76.3 m)

Cash From Investing Activities

(210.1 m)(45.5 m)(76.3 m)

Cash From Financing Activities

198.9 m33.4 m(18.6 m)

Interest Paid

8.2 m

Income Taxes Paid

(4.7 m)(3.6 m)(4.6 m)
Y, 2016

Financial Leverage

1.6 x

Emergent Biosolutions Market Value History

Emergent Biosolutions Online and Social Media Presence

Emergent Biosolutions News and Updates

Emergent Biosolutions Company Life and Culture

You may also be interested in